Efficacy of triple-therapy with boceprevir (BOC) and telaprevir (TPV) to treat the hepatitis C virus coinfection in HIV-positive patients (HIV/HCV).

Trial Profile

Efficacy of triple-therapy with boceprevir (BOC) and telaprevir (TPV) to treat the hepatitis C virus coinfection in HIV-positive patients (HIV/HCV).

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs Boceprevir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top